Labcorp Holdings Inc. $LH Shares Purchased by Dakota Wealth Management

Dakota Wealth Management raised its position in Labcorp Holdings Inc. (NYSE:LH) by 98.6% during the 3rd quarter, Holdings Channel.com reports. The firm owned 10,303 shares of the medical research company’s stock after acquiring an additional 5,116 shares during the quarter. Dakota Wealth Management’s holdings in Labcorp were worth $2,958,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds also recently made changes to their positions in LH. Vanguard Group Inc. boosted its position in shares of Labcorp by 1.6% during the second quarter. Vanguard Group Inc. now owns 9,879,225 shares of the medical research company’s stock worth $2,593,395,000 after buying an additional 156,717 shares during the period. State Street Corp raised its stake in Labcorp by 0.9% during the 2nd quarter. State Street Corp now owns 3,863,039 shares of the medical research company’s stock valued at $1,014,086,000 after acquiring an additional 36,003 shares in the last quarter. Geode Capital Management LLC grew its stake in shares of Labcorp by 2.2% in the second quarter. Geode Capital Management LLC now owns 2,113,460 shares of the medical research company’s stock worth $552,445,000 after purchasing an additional 44,630 shares in the last quarter. JPMorgan Chase & Co. grew its stake in shares of Labcorp by 3.5% in the second quarter. JPMorgan Chase & Co. now owns 1,303,307 shares of the medical research company’s stock worth $342,131,000 after purchasing an additional 43,661 shares in the last quarter. Finally, Norges Bank acquired a new position in shares of Labcorp during the second quarter valued at $263,070,000. Institutional investors own 95.94% of the company’s stock.

Labcorp Stock Up 0.8%

LH stock opened at $287.56 on Wednesday. The firm has a market cap of $23.84 billion, a PE ratio of 27.49, a P/E/G ratio of 1.95 and a beta of 1.03. Labcorp Holdings Inc. has a 12 month low of $209.38 and a 12 month high of $293.72. The company has a debt-to-equity ratio of 0.60, a current ratio of 1.42 and a quick ratio of 1.23. The firm has a 50 day simple moving average of $266.52 and a 200 day simple moving average of $269.64.

Labcorp (NYSE:LH) last posted its quarterly earnings results on Tuesday, February 17th. The medical research company reported $4.07 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.95 by $0.12. Labcorp had a net margin of 6.28% and a return on equity of 16.16%. The firm had revenue of $3.52 billion for the quarter, compared to analyst estimates of $3.56 billion. During the same quarter in the previous year, the business posted $3.45 earnings per share. The firm’s quarterly revenue was up 5.6% compared to the same quarter last year. Labcorp has set its FY 2026 guidance at 17.550-18.250 EPS. Equities research analysts forecast that Labcorp Holdings Inc. will post 16.01 earnings per share for the current fiscal year.

Labcorp Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Thursday, March 12th. Stockholders of record on Friday, February 27th will be issued a dividend of $0.72 per share. This represents a $2.88 annualized dividend and a dividend yield of 1.0%. The ex-dividend date of this dividend is Friday, February 27th. Labcorp’s dividend payout ratio is currently 27.53%.

Insiders Place Their Bets

In related news, EVP Jonathan C. Meltzer sold 87 shares of Labcorp stock in a transaction dated Thursday, February 12th. The stock was sold at an average price of $290.42, for a total value of $25,266.54. Following the transaction, the executive vice president owned 2,782 shares of the company’s stock, valued at approximately $807,948.44. This trade represents a 3.03% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Adam H. Schechter sold 5,273 shares of the business’s stock in a transaction dated Wednesday, February 11th. The stock was sold at an average price of $284.38, for a total value of $1,499,535.74. Following the sale, the chief executive officer owned 87,343 shares in the company, valued at approximately $24,838,602.34. The trade was a 5.69% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Company insiders own 0.84% of the company’s stock.

Analyst Upgrades and Downgrades

LH has been the subject of several research analyst reports. Robert W. Baird upped their price objective on shares of Labcorp from $313.00 to $326.00 and gave the stock an “outperform” rating in a report on Wednesday, February 18th. Weiss Ratings raised shares of Labcorp from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Tuesday, February 10th. JPMorgan Chase & Co. raised their price objective on shares of Labcorp from $319.00 to $330.00 and gave the company an “overweight” rating in a research note on Wednesday, February 18th. UBS Group dropped their target price on Labcorp from $325.00 to $320.00 and set a “buy” rating on the stock in a report on Wednesday, October 29th. Finally, Piper Sandler increased their price target on Labcorp from $270.00 to $300.00 and gave the company a “neutral” rating in a research note on Tuesday. Ten equities research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $304.42.

Labcorp Company Profile

Laboratory Corporation of America Holdings, commonly known as Labcorp (NYSE: LH), is a global life sciences company that provides comprehensive clinical laboratory and drug development services. The company operates a broad network of laboratories, patient service centers and specialty testing sites to deliver diagnostic information and testing solutions that support patient care, clinical decision-making and population health initiatives.

Labcorp’s core businesses encompass clinical laboratory testing and pharmaceutical development services.